Scarica l'app Stockscreener
0.70
4.48%
0.03
Dopo l'orario di chiusura:
.72
0.02
+2.86%
Precedente Chiudi:
$0.67
Aprire:
$0.67
Volume 24 ore:
57,654
Relative Volume:
0.27
Capitalizzazione di mercato:
$9.73M
Reddito:
$17.44M
Utile/perdita netta:
$-21.23M
Rapporto P/E:
-0.313
EPS:
-2.2361
Flusso di cassa netto:
$-17.60M
1 W Prestazione:
+14.75%
1M Prestazione:
-10.54%
6M Prestazione:
-69.03%
1 anno Prestazione:
-71.89%
Intervallo 1D:
$0.67
$0.70
Intervallo di 1 settimana:
$0.6163
$0.754
Portata 52W:
$0.545
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Nome
Vivos Therapeutics Inc
Settore
Industria
Telefono
(866)908-4867
Indirizzo
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.70 | 9.31M | 17.44M | -21.23M | -17.60M | -2.2361 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Vivos Therapeutics Inc Borsa (VVOS) Ultime notizie
Vivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts By GuruFocus - Investing.com Canada
Vivos Therapeutics Balances Rapid Growth With Cash Strain - TipRanks
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2026 Earnings Call Transcript - Insider Monkey
VVOS Stock Chart | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
Vivos Therapeutics Earnings Call: Growth Meets Cash Strain - TipRanks
Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vivos Therapeutics (NASDAQ: VVOS) Q1 2026 loss and going concern risk - Stock Titan
Vivos Therapeutics reports 70% revenue increase in Q1 2026 - Investing.com
Vivos Therapeutics reports 70% revenue increase in Q1 2026 By Investing.com - Investing.com Australia
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - The Manila Times
BRIEF-Vivos Therapeutics Q1 Net Income USD -7.751 Million - TradingView
Press Release: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - Moomoo
VVOS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vivos Therapeutics Delays Quarterly Filing - TipRanks
Vivos Therapeutics (VVOS) delays Q1 10-Q; preliminary revenue up ~70% - Stock Titan
Armistice Capital (NASDAQ: VVOS) reports 8.27% holding in Vivos Therapeutics - Stock Titan
TradingKey - TradingKey
[EFFECT] Vivos Therapeutics, Inc. SEC Filing - Stock Titan
Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential - MSN
Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges - TipRanks
3.96M warrant shares registered by Vivos (VVOS) for resale; $2.09 strike - Stock Titan
VVOS Forecast, Price Target & Analyst Ratings | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
Vivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47 - MSN
Broadcom, Vivos Therapeutics and 3 stocks to watch heading into Monday - MSN
Vivos Therapeutics (NASDAQ: VVOS) registers 3.96M warrant-linked shares for resale - Stock Titan
VVOS Should I Buy - Intellectia AI
Vivos Therapeutics receives Nasdaq notice for stockholders’ equity deficiency - Investing.com
Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Equity shortfall puts Vivos Therapeutics (NASDAQ: VVOS) at Nasdaq delisting risk - Stock Titan
Qorvo To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Vivos Reports 16% Revenue Increase in 2025 Following Business Model Shift - Sleep Review
Vivos Therapeutics stock price target lowered to $2.50 by H.C. Wainwright - Investing.com Australia
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM ESTShow #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Viv - ACCESS Newswire
H.C. Wainwright Maintains Vivos Therapeutics(VVOS.US) With Buy Rating, Cuts Target Price to $2.5 - 富途牛牛
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics (VVOS) Stock: Why Cash Position (Freefalls) 2026-04-16Trending Entry Points - UBND thành phố Hải Phòng
Vivos Therapeutics Balances Growth Hopes With Cash Strain - TipRanks
Vivos Therapeutics Reports Full Year 2025 Financial Results - ADVFN
Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
Vivos Therapeutics Reports 16% Revenue Growth in 2025, Advances Sleep Center Integration and Eyes Cash Flow Positive Operations - Minichart
Vivos Therapeutics Pivots to Medical-Provider Focused Model with Sleep Center of Nevada Acquisition to Expand Sleep Apnea Solutions 91 - Minichart
Earnings call transcript: vivos beats Q4 2025 earnings expectations - Investing.com UK
VVOS: 2025 revenue rose 16% as SCN integration fueled growth, with further expansion planned for 2026 - TradingView
Earnings Call Summary | Vivos Therapeutics(VVOS.US) Q4 2025 Earnings Conference - 富途牛牛
Vivos Therapeutics Inc Azioni (VVOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.59%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):